Related Experiment Videos
[Therapeutic strategy for prostate specific antigen (PSA) failure after radical prostatectomy]
Hidefumi Kinoshita1, Toshiyuki Kamoto, Michihide Mitsumori
1Department of Urology, Kyoto University Graduate School of Medicine, 54 Shogoin-kawaramachi, Sakyo-ku, Kyoto 606-8507, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|February 1, 2003
Summary
Prostate specific antigen (PSA) failure after prostatectomy affects many men. Salvage radiotherapy offers a potentially curative option for PSA failure, showing promising recurrence-free rates and increasing importance in treatment strategies.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Context:
- Prostate specific antigen (PSA) failure is a common challenge post-radical prostatectomy, affecting 20%-50% of patients.
- Current management strategies for PSA failure lack consensus.
- Salvage radiotherapy is emerging as a significant treatment option.
Purpose:
- To highlight the role and effectiveness of salvage radiotherapy in managing prostate specific antigen (PSA) failure after radical prostatectomy.
- To emphasize the curative intent of salvage radiotherapy compared to other treatments like endocrine therapy.
Summary:
- Prostate specific antigen (PSA) failure, defined by rising PSA levels after radical prostatectomy, occurs in a substantial proportion of patients.
- Salvage radiotherapy demonstrates efficacy in treating PSA failure, with reported recurrence-free rates ranging from 20% to 70%.
- The curative aim of salvage radiotherapy distinguishes it from palliative or hormonal treatments, positioning it as a key therapeutic approach.
Impact:
- Salvage radiotherapy is poised to become a more critical component of post-prostatectomy care for managing PSA recurrence.
- Improved understanding and application of salvage radiotherapy can enhance long-term outcomes for patients experiencing PSA failure.
- This approach offers a chance for cure, potentially improving survival and quality of life for affected individuals.